Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

23andMe

- PMLiVE

Novo Nordisk shares promising phase 3 data for semaglutide in diabetes and chronic kidney disease

An estimated 40% of people living with type 1 or type 2 diabetes will develop CKD in their lifetime

- PMLiVE

UKHSA publishes five-year strategy to detect risk-posing pathogens in UK

The strategy will help to improve the UK's response to infectious disease threats

- PMLiVE

Incisionless device to transform diabetes, liver disease and severe obesity treatment

ForePass replicates common invasive metabolic surgeries without making any incisions

- PMLiVE

Novo Nordisk’s once-weekly IcoSema shows promise in phase 3a type 2 diabetes trial

IcoSema showed non-inferiority to daily insulin treatment in reducing blood glucose levels

- PMLiVE

Risk calculator to prevent heart attacks and strokes in type 2 diabetes patients

About one-third of adults living with diabetes die from a heart or circulatory disease

- PMLiVE

Eli Lilly’s tirzepatide injection approved by MHRA and FDA for weight loss in adults

The drug has been authorised for use alongside a reduced-calorie diet and physical activity

- PMLiVE

AstraZeneca’s Forxiga shows promise in paediatric type 2 diabetes trial

The prevalence of type 2 diabetes in children and adolescents is increasing globally

- PMLiVE

Eli Lilly’s Mounjaro receives NICE recommendation to treat type 2 diabetes

Around 180,000 patients with type 2 diabetes could benefit from the new treatment option

- PMLiVE

Eli Lilly/Boehringer’s Jardiance for children with type 2 diabetes accepted by FDA

The incidence of type 2 diabetes in children has nearly doubled over the past two decades

- PMLiVE

Novo Nordisk’s type 2 diabetes drug approved by FDA as first-line option

Rybelsus was initially approved in 2019 as a second-line treatment

- PMLiVE

Oramed’s oral insulin candidate fails to meet phase 3 targets

The company said it expects to end its oral insulin clinical activities for type 2 diabetes

- PMLiVE

Novo Nordisk’s insulin icodec shows promise as once-weekly type 2 diabetes treatment

Currently, the basal insulin products with the longest duration are injected once daily

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links